Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02108652 · OUTCOME

Overall Survival (OS)

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) · Source last updated 2024-03-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline until death (data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)

What was measured

OS was defined as the time from start of treatment to the time of death from any cause on study.

Analysis population: Cohort 2 ITT population

Groups in this outcome

Cohort 2: Participants With Second-line or Beyond Treatments

Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 2: Participants With Second-line or Beyond Treatments310

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 2: Participants With Second-line or Beyond Treatments7.9Not reported6.79.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.7
        upper Limit
        9.3
        value
        7.9
denoms
  1. counts
    1. group Id
      OG000
      value
      310
    units
    Participants
description
OS was defined as the time from start of treatment to the time of death from any cause on study.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
    id
    OG000
    title
    Cohort 2: Participants With Second-line or Beyond Treatments
param Type
MEDIAN
population Description
Cohort 2 ITT population
reporting Status
POSTED
time Frame
Baseline until death (data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice